Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

ABSTRACT: The purpose of the study is to investigate the safety, tolerability, and preliminary anti-neoplastic activity of S095029 alone and in combination with Sym021 in patients with advanced solid tumor malignancies followed by an expansion phase of triple combinations.

DISEASE(S): Solid Tumor,Advanced Solid Tumors,Colorectal Neoplasms,Neoplasms

PROVIDER: 2398753 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Arabidopsis thaliana vegetative part: Col-0 vs. shr scl23 scr triple mutant

Project description:Transcriptional profiling of the vegetative part of Arabidopsis comparing wild type with the shr scl23 scr triple mutant. The latter is produced by crossing the strong null alleles of shr (shr-2), scl23 (scl23-1) and scr (scr-5). The goal was to determine the effects of the GRAS transcription factors SHR, SCL23 and SCR on growth and development of the Arabidopsis shoot system by global transcriptome analysis. Two-condition experiment: Col-0 vs. shr scl23 scr triple mutant. Biological replicates: 2 WT vs. triple mutant replicates, 2 WT vs. triple mutant replicates dye-swap replicates.

2012-10-11 | E-GEOD-41478 | biostudies-arrayexpress

Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.

Project description: Not available

| S-EPMC5804097 | biostudies-literature

Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients

Project description:Evidence suggests that BRCA1 mutation associated tumors have increased sensitivity to DNA damaging agents like cisplatin. Sporadic triple negative breast cancers (TNBC) have many phenotypic similarities to BRCA1 tumors and may have a similar sensitivity to cisplatin. We tested the efficacy of cisplatin monotherapy in 28 TNBC patients in a single arm neoadjuvant trial with outcome measured by pathologic treatment response quantified using the Miller-Payne scale. We used microarrays gene expression profiles to determine tumor subtype of each trial tumor sample and to test various expression signatures for association with pathologic response to cisplatin. Pretreatment tumor samples from the clinical trial (N=24 with adequate tissue) were used for RNA extraction, linear amplification, biotin labeling and hybridization to Affymetrix U133 plus 2.0 arrays. A reference set of 51 primary breast tumors representing all subtypes of breast cancer were processed in a similar manner to include linear amplification, and hybridized to Affymetrix arrays.

2009-11-04 | E-GEOD-18864 | biostudies-arrayexpress

Distinct Cellular Mechanisms Underlie Chemotherapies and Their Combinations with PD-L1 Checkpoint Inhibitor in Triple-Negative Breast Cancer [TNBC]

Project description:The combination of immune checkpoint blockade (ICB) and chemotherapy holds promise for treating triple-negative breast cancer (TNBC), yet the underlying mechanisms remain incompletely understood. Here, we integrated previously published and newly generated single-cell RNA sequencing (scRNA-seq) data to investigate the tumor immune microenvironment (TIME) in advanced TNBC patients receiving various therapies, including paclitaxel, nab-paclitaxel, and their combinations with an anti-PD-L1 antibody atezolizumab. Notably, compared to atezolizumab plus paclitaxel, atezolizumab plus nab-paclitaxel primarily rewired TCF7+ stem-like effector memory CD8 T cells (Tsem) and CD4 follicular helper T (Tfh) cells. Nab-paclitaxel, but not paclitaxel, predominantly modulated the myeloid compartment, expanding mast cells and pro-inflammatory macrophage subsets. Our analyses in human TNBC and murine models highlighted the crucial role of mast cells in orchestrating anti-tumor immune responses, likely by recruiting and activating T cells and B cells. In vivo experiments demonstrated that activating mast cells alongside PD-L1 blockade significantly attenuated tumor progression, suggesting mast cells as a promising adjunct for enhancing ICB therapy efficacy.

2025-02-12 | GSE266919 | GEO

Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients

2009-11-04 | GSE18864 | GEO

Distinct Cellular Mechanisms Underlie Chemotherapies and Their Combinations with PD-L1 Checkpoint Inhibitor in Triple-Negative Breast Cancer [TNBC]

Project description:Distinct Cellular Mechanisms Underlie Chemotherapies and Their Combinations with PD-L1 Checkpoint Inhibitor in Triple-Negative Breast Cancer [TNBC]

| PRJNA1108722 | ENA

Arabidopsis thaliana vegetative part: Col-0 vs. shr scl23 scr triple mutant

2012-10-11 | GSE41478 | GEO

Chemical Probes Reveal Interferon-Driven Biomarkers of PRMT5 Inhibitor Sensitivity and Guide Synergistic Therapy in Triple-Negative Breast Cancer

Project description:This study employed 10x Genomics single-cell RNA sequencing (scRNA-seq) technology to investigate the effects of the combination of the PRMT5 inhibitor LLY283 and the PARP inhibitor Olaparib, as well as the triple combination with PD-1 blockade, on the tumor microenvironment in a mouse model of triple-negative breast cancer (TNBC). Our research uncovers the regulatory effects of these drugs and their combinations on the tumor microenvironment, providing new strategies and insights for future clinical therapy.

2025-03-20 | GSE292508 | GEO

Anti-Neoplastic Activity of Estrogen Receptor Beta in Chemoresistant Triple-Negative Breast Cancer

Project description:Anti-Neoplastic Activity of Estrogen Receptor Beta in Chemoresistant Triple-Negative Breast Cancer

| PRJNA1280979 | ENA

Phage-Antibiotic Combinations Against Klebsiella pneumoniae

Project description:Phage-Antibiotic Combinations Against Klebsiella pneumoniae

| PRJNA995503 | ENA